(Reuters) - AstraZeneca said Monday it had struck a deal to buy U.S.-based drug developer CinCor Pharma Inc. for up to $1.8 billion to increase its stock of heart and kidney drugs.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
